Loading...
•
Jun 30
Royalty Pharma Q2 2025 Earnings Report
Royalty Pharma reported strong financial results for the second quarter of 2025, driven by double-digit growth in Royalty Receipts and Portfolio Receipts, and raised its full-year 2025 guidance for Portfolio Receipts.
Key Takeaways
Royalty Pharma delivered excellent second quarter 2025 results, with Portfolio Receipts growing 20% to $727 million and Royalty Receipts increasing 11% to $672 million. The company also completed the acquisition of its external manager, becoming an integrated company, and announced a significant funding agreement with Revolution Medicines. Royalty Pharma repurchased $1 billion of its Class A ordinary shares in the first half of the year, demonstrating a strong fundamental outlook.
Portfolio Receipts increased by 20% to $727 million in Q2 2025, primarily driven by Voranigo, Trelegy, Evrysdi, and Tremfya, and a one-time payment.
Royalty Receipts grew by 11% to $672 million in Q2 2025, attributed to strong performance from key products.
Royalty Pharma completed the acquisition of its external manager, RP Management, LLC, in May 2025, becoming an integrated company.
The company repurchased $277 million of Class A ordinary shares in Q2 2025, contributing to a total of $1 billion in repurchases during the first half of 2025.
Royalty Pharma
Royalty Pharma
Royalty Pharma Revenue by Segment
Revenue by Segment
Cystic Fibrosis Franchise Revenue
CapyFin.comTrelegy Revenue
CapyFin.comTysabri Revenue
CapyFin.comEvrysdi Revenue
CapyFin.comXtandi Revenue
CapyFin.comImbruvica Revenue
CapyFin.comPromacta Revenue
CapyFin.comTremfya Revenue
CapyFin.comCabometyx/Cometriq Revenue
CapyFin.comSpinraza Revenue
CapyFin.comTrodelvy Revenue
CapyFin.comErleada Revenue
CapyFin.comOther Products Revenue
CapyFin.com Forward Guidance
Royalty Pharma raised its full-year 2025 guidance for Portfolio Receipts, expecting growth of 9% to 12%. The guidance assumes a negligible foreign exchange impact and excludes contributions from future transactions.
Positive Outlook
- Expected Portfolio Receipts of $2.9 billion to $2.975 billion for full year 2025.
- Anticipated Portfolio Receipts growth of 9% to 12% in 2025.
- Payments for operating and professional costs expected to decrease in H2 2025 due to internalization.
- Estimated total interest paid of approximately $275 million for 2025, partially offset by interest collected.
- Guidance assumes no major unforeseen adverse events or changes in foreign exchange rates.
Challenges Ahead
- Guidance excludes contributions from transactions announced subsequent to the report date.
- Operating and professional costs include approximately $70 million in one-time payments for internalization and bond sale.
- Projections assume no additional debt financing in 2025, including no drawdown on the revolving credit facility.
- The term loan has a variable interest rate, which could fluctuate.
- Overall, the forward guidance is overwhelmingly positive with minimal explicit negatives mentioned.